The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 13, 2018. Its latest SEC filing is a 15-12B from Sep 25, 2019.
10-Q for Q3 FY2018, filed Nov 13, 2018
The sections below describe the company as of the FY2017 annual report.
Sells branded prescription medicines for pain, insomnia and migraine, and generic medicines to drug wholesalers, specialty pharmacies and retail pharmacies.
10-K for FY2017, filed Mar 8, 2018We are a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing…View ↗
We target underserved segments, such as central nervous system (CNS) indications, including pain, neurology, and psychiatry, as well as…View ↗
Chronic Pain: Zohydro® ER (hydrocodone bitartrate) with BeadTekTM, an extended-release opioid agonist indicated for the management of pain…View ↗
We market and sell our non-core products, including generics, through our wholly owned subsidiaries, Cypress and Macoven. We also market…View ↗
Our customers consist of drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers and grocery store pharmacies in the…View ↗
The company sells products to customers, with sales occurring on delivery—or when consigned products are removed for shipment to patients. It also receives royalties based on third-party product sales.
10-K for FY2017, filed Mar 8, 2018
$146.1M
10-K for FY2017, filed Mar 8, 2018
$146.1M ↗
Drug wholesalers are the company's primary direct customers; they distribute products to retail drug stores, mass merchandisers and grocery store pharmacies. Specialty pharmacies are also customers.
10-K for FY2017, filed Mar 8, 2018Our customers consist of drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers and grocery store pharmacies in the…View ↗
10-K for FY2017, filed Mar 8, 2018
Gross Product Sales 2017 2016 McKesson Corporation 34% 36% AmerisourceBergen Drug Corporation 30% 31% Cardinal Health, Inc. 24% 26% Total…View ↗
10-Q for Q3 FY2018, filed Nov 13, 2018
−$11.8MView ↗
8-K, filed Jun 26, 2019
The Plan became effective on June 24, 2019.View ↗
8-K, filed May 21, 2019
Following consummation of the Asset Sale, on May 15, 2019, John A. Sedor, chairman of the Board of Directors of the Company (the “Board”)…View ↗
8-K, filed May 6, 2019
On April 30, 2018, the Company and certain of its subsidiaries (together, the “Sellers”) completed the previously announced sale of…View ↗
8-K, filed Feb 27, 2019
On February 18, 2019 (the “Petition Date”), Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) and Pernix’s wholly-owned…View ↗
Shrank. Revenue fell 17% in 2 years, from $175.9M in FY2015 to $146.1M in FY2017, about 9% a year.
Treximet promotion
The older report says Pernix promoted Treximet through its specialty sales force. The latest report says it stopped promotion after restructuring and began distributing an authorized generic alongside the branded product.
10-K for FY2014, filed Mar 2, 2015 10-K for FY2017, filed Mar 8, 2018We promote Treximet in the United States through our nationwide specialty sales force, which covers approximately 100 territories. Treximet…View ↗
Competes with Teva, Depomed, Purdue Pharma, Pfizer, Collegium, Egalet, and Valeant
10-K for FY2017, filed Mar 8, 2018Our ability to continue to grow requires that we compete successfully with other specialty pharmaceutical companies for product and product…View ↗
Loading...
